Innovative Therapy Focus Arrevus specializes in developing novel treatments for rare and unmet medical conditions such as cystic fibrosis and antibiotic-resistant infections, presenting opportunities for partnerships or supply of specialized biotechnologies and therapeutics.

Recent Acquisition Advantage Following its acquisition by Aceragen in late 2021, Arrevus’s ongoing clinical programs may require continued research support, CAPEX funding, or collaborative opportunities in orphan drug development and clinical trial management.

Funding and Grants With over $4.5 million in funding and multiple grants aimed at antibiotic resistance and infectious diseases, there are potential avenues for companies offering specialized research tools, grant management software, or clinical trial services.

Regulatory Milestones The company has secured FDA orphan drug designation and FDA approval pathways for key products, creating opportunities for consulting, regulatory compliance, and market access services to accelerate commercialization efforts.

Limited Revenue, Growing Needs While revenue remains below $1 million, Arrevus’s active research pipeline and recent clinical stage advancements suggest an increasing need for innovative laboratory equipment, biotech reagents, and contract research organizations to support their developmental activities.